Browsing Tag
Olezarsen
3 posts
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Ionis and SOBI’s olezarsen cuts pancreatitis risk by 85% in sHTG phase 3 trials
Olezarsen showed 85% reduction in acute pancreatitis for severe hypertriglyceridemia. See what this means for Sobi, Ionis, and upcoming EMA and FDA filings.
Ionis Pharmaceuticals’ olezarsen reduces pancreatitis by 85% in late-stage sHTG trial
Ionis Pharmaceuticals reports 85% drop in pancreatitis with olezarsen in Phase 3 sHTG trial. Find out what the AHA late-breaker results could mean for FDA approval.